STAT+: Skylar Bio kicks off new gene therapy trial for deafness

AI Summary

Skylar Bio has initiated a new gene therapy clinical trial aimed at treating deafness. The race among biotech startups from the U.S., France, and China focuses on developing therapies targeting various genetic mutations responsible for hearing loss.

Biotech startups in the U.S., France, and China are racing to bring new gene therapies for deafness by targeting different genetic mutations.